Form 4: Maravai LifeSciences Director Jessica Hopfield Receives Equity Award

Maravai LifeSciences Holdings, Inc. Director Jessica Hopfield was granted 89,139 restricted stock units (RSUs) valued at $2.16 per share, as part of the company's 2020 Omnibus Incentive Plan.

Summary

• Jessica Hopfield, a Director at Maravai LifeSciences Holdings, Inc. (MRVI), acquired 89,139 shares of Class A Common Stock.
• The acquisition occurred on June 16, 2025, and was in the form of Restricted Stock Units (RSUs).
• The RSUs were awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.
• The price per share for the acquired RSUs was $2.16.
• These RSUs will vest in full upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
• Following this transaction, Jessica Hopfield beneficially owns 199,907 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The filing reports a routine equity award to a director, which is a positive for aligning management's interests with shareholders, but it is a standard compensation event rather than a significant operational or financial announcement.

Positives

• The grant of restricted stock units to a director aligns their interests with those of shareholders, as the value of their compensation is tied to the company's stock performance.
• It represents a standard form of equity compensation, indicating ongoing commitment to retaining and incentivizing key personnel.

Future Outlook

The granted Restricted Stock Units are set to vest in full upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders, indicating a future increase in the director's vested equity stake.

Industry Context

This filing reflects a routine equity compensation practice common across the life sciences and biotechnology industries, where stock-based awards are used to attract, retain, and incentivize directors and executives, aligning their long-term interests with company performance.

Related Party Transactions

• The grant of 89,139 Restricted Stock Units to Jessica Hopfield, a Director of Maravai LifeSciences Holdings, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value creation, as the value of the award is tied to the company's stock performance. It also represents a minor potential for future dilution upon vesting.
• Employees: While specific to a director, this type of equity compensation reflects a broader company strategy for incentivizing key personnel.
• Director (Jessica Hopfield): Receives equity compensation, increasing her stake and aligning her long-term financial interests with the company's success.

Next Steps

• Vesting of the 89,139 Restricted Stock Units upon the earlier of June 16, 2026, or the date of the 2026 annual meeting of stockholders.

Key Dates

Keywords

Maravai LifeSciences, MRVI, SEC Form 4, Restricted Stock Units, RSU, Equity Award, Director Compensation, Insider Transaction, Stock Grant, Omnibus Incentive Plan